[1]张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(4):15-18,23.
　ZHANG Yu-wan,TAN Zai-xiang,LU Ya-juan.Implementation Status and Optimized Suggestions of the "Dual-Channel" Model for National Negotiation Drugs——Taking S City as An Example[J].Journal Press of Health Economics Research,2022,39(4):15-18,23.
点击复制

国家谈判药品“双通道”模式实施现状及优化建议
——以S市为例
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年4期
页码:
15-18,23
栏目:
药械管理
出版日期:
2022-03-28

文章信息/Info

Title:
Implementation Status and Optimized Suggestions of the "Dual-Channel" Model for National Negotiation Drugs
——Taking S City as An Example
作者:
张钰婉1; 谈在祥1; 2; 卢亚娟1
1.徐州医科大学管理学院，江苏 徐州 221004
2.徐州医科大学附属医院，江苏 徐州 221006
Author(s):
ZHANG Yu-wan;  TAN Zai-xiang;  LU Ya-juan
School of Management, Xuzhou Medical University, Xuzhou Jiangsu 221004, China
关键词:
国家谈判药品; 双通道; 地方实践
Keywords:
national negotiated drugs;  dual-channel;  local practice
分类号:
R19
文献标志码:
A
摘要:
目的：分析国家谈判药品“双通道”运行现状，并提出政策建议。方法：对S市国谈药品“双通道”政策进行梳理，以乳腺癌靶向药物“注射用曲妥珠单抗”为例，研究国谈药品的管理和使用情况。结果：S市国谈药品“双通道”模式实践较早，具有较好的借鉴意义，但在运行中存在一些共性问题。结论：医保部门要根据地方实际，从医院、医药、医保三个方面优化政策，打通国谈药品入院通道、保障药品质量、加强信息化建设，确保“双通道”模式的顺利落地。
Abstract:
Objective To analyze the current situation of the "dual-channel" operation of national negotiated drugs, and to put forward policy suggestions. Methods This study sorted out the "dual-channel" policy of national negotiated drugs in S City, taking the breast cancer targeted drug " trastuzumab for injection" as an example to investigate the management and use of national negotiated drugs. Results "Dual-channel" model of national negotiated drugs in S City was earlier carried out. This practice was good to take as a reference, but it still had some common problems. Conclusion The medical insurance department should optimize the policies from the three aspects (hospital, medicine and medical insurance) according to the local actual situation. And it is suggested to open up the admission channel for national negotiated drugs, guarantee the quality, strengthen the construction of information technology, and ensure the successful implementation of the "dual-channel" model.

参考文献/References:

[1] 李凯悦，刘辉，蒋倩.历年国家医保谈判药品概况与分析——抗肿瘤药品专题 [J].肿瘤药学，2021，11（2）：229-235.
[2] 陈玲玲，徐伟，尚波波，等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究，2020，37（12）：17-20.
[3] 谢金平，邵蓉.国家医保谈判药品省级落地管理典型模式研究 [J].中国卫生经济，2020，39（6）：42-46.
[4] 徐翠玉.曲妥珠单抗在乳腺癌患者治疗中的心脏毒性分析 [J].世界复合医学，2020，6（7）：164-166.
[5] 廖化.国家谈判药品落地的陕西实践 [J].中国医疗保险， 2020（9）: 44-46.
[6] 刘畅，文光慧.天津某三甲医院国谈药品外配处方现状调查分析 [J].中国卫生标准管理，2019，10（10）：46-48.
[7] 陈烨，丁锦希，柳婷，等.国家谈判药品门诊医保待遇现状、问题及完善措施 [J].中国药科大学学报，2020，51（5）：628-634.

相似文献/References:

[1]梁 冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,(05):42.
　LIANG Bing,WANG Qian-qiang,CHEN Feng-lei,et al.Impact of National Negotiation Drugs on Medical Insurance Management in General Hospitals and Countermeasures[J].Journal Press of Health Economics Research,2020,(4):42.
[2]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(4):17.
[3]严 晶,张 燕.DRG付费下国家谈判药品政策落地的实践[J].卫生经济研究,2021,38(12):20.
　YAN Jing,ZHANG Yan.Practice of National Negotiated Drug Policy Implementation under DRG Payment[J].Journal Press of Health Economics Research,2021,38(4):20.
[4]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(4):8.
[5]王宁锋,李雪竹,张 慧.国谈药单行支付政策研究[J].卫生经济研究,2024,41(06):16.
　WANG Ningfeng,LI Xuezhu,ZHANG Hui.Study on One-way Payment Policy for the State-negotiated Drugs[J].Journal Press of Health Economics Research,2024,41(4):16.
[6]郭孟子,李紫航,陈艺璇,等.“三医”协同视角下国谈药“双通道”高质量发展研究[J].卫生经济研究,2024,41(08):4.
　GUO Mengzi,LI Zihang,CHEN Yixuan,et al.Study on the High-quality Development of the "Dual channel" of National Negotiated Drugs from the Perspective of "Three Medical" Synergy[J].Journal Press of Health Economics Research,2024,41(4):4.

更新日期/Last Update: 2022-03-28